Freedom Capital Markets Downgrades AtriCure to Hold, Raises Price Target to $57
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsDowngradesPrice Target
Freedom Capital Markets analyst Keith Hinton downgrades AtriCure (NASDAQ:ATRC) from Buy to Hold and raises the price target from $43 to $57.
Freedom Capital Markets analyst Keith Hinton downgrades AtriCure (NASDAQ:ATRC) from Buy to Hold and raises the price target from $43 to $57.